AbbVie (NYSE: ABBV) announced results from a Phase 2 trial evaluating mirvetuximab soravtansine-gynx (ELAHERE) combined with carboplatin in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE